NCODA Logo

Darolutamide EMR Tool

The new treatment paradigm in prostate cancer focuses on preventing metastases in men. Identifying these patients earlier in their disease course allows optimization of the continuum of care.

Improved methods and practices to enable professionals to identify then offer darolutamide (Nubeqa®) to appropriate patients at the right time has taken precedence as the prostate cancer paradigm has shifted towards detecting early metastatic disease or treating active metastatic disease aggressively early in their clinical course. Please utilize instructions below to help with your patients.

Step 1: Run a report for prostate cancer patients:

Select Electronic Medical Record (EMR) System for instructions


Step 2: Review Chart(s) 

  • Conduct a clinical assessment from the report ran to proactively identify non-metastatic castration resistant prostate cancer (nmCRPC) patients
  • Work closely and proactively with provider to determine each unique patient’s anticipated treatment plan
  • Consider discussing treatment plan of darolutamide (Nubeqa®) utilization with provider
  • Consider monthly follow-up plan within the EMR during surveillance

Step 3: Utilize NCODA PQI

  • Ensure appropriate dosing/modifications, and labs
  • Appropriately screen for drug interactions 
  • Ensure appropriate patient education and understanding

Step 4:

  • Visit online resources for more information and appropriate use of darolutamide in nmCRPC patients
  • Examples: